Lipidor strengthens its operational team and recruits Supply Chain & Operations Manager
STOCKHOLM, Sweden, 25 March 2022 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) is announcing that the company has strengthened its operational team with the recruitment of Marianne Avila to the position of Supply Chain & Operations Manager.
At Lipidor, Marianne Avila will strengthen the operational team and contribute to development, primarily in purchasing and logistics, which are vital functions as the company approaches commercialization. Lipidor already has a commercial agreement in place, and work is underway for additional commercial contracts, for the company’s drug candidates for the treatment of psoriasis.
Marianne Avila took up the newly created position during the month of March, and reports to the Chief Development Officer, Anders Hagman. Her background and experience include areas such as purchasing, logistics, sales and regulatory issues in the pharmaceutical industry, including at FrostPharma AB, Air Liquide Gas AB, AstraZeneca and from Stockholm Regional Council, where she worked in procurement of pharmaceuticals. Marianne holds a master’s degree in molecular biology from Purdue University in the United States.
“It is gratifying to welcome Marianne Avila to Lipidor. Recruitment to the new position of Supply Chain & Operations Manager is a natural step in strengthening our operational team, ahead of the company’s continued development. Lipidor is now entering a new phase and we are preparing for a commercialization of our psoriasis candidates,” says Ola Holmlund, CEO of Lipidor.
The information was provided for publication by Lipidor’s CEO on 25th March 2022 at 11.30am (CET).
For more information, please contact:
Ola Holmlund, CEO
Phone: +46 (0)72 50 70 369
Erik Penser Bank AB
Telephone: +46 (0)8 463 80 00
About Lipidor AB
Lipidor AB (www.lipidor.se) is a Swedish, Stockholm-based research and development company with a pipeline of pharmaceutical development projects in preclinical and clinical phases. The Company develops topical medical products for the treatment of diseases such as psoriasis, acne vulgaris, bacterial skin infections and atopic dermatitis by reformulation of proven pharmaceutical substances.